Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068369 | 1.00 | KDM4E (0.32) | KDM4EKMT2A | |
| SCHEMBL1169089 | 0.72 | — | — | |
| SCHEMBL26786473 | 0.64 | KDM4E (0.33) | KDM4EKMT2A | |
| SCHEMBL7589446 | 0.64 | KDM4E (0.31) | KDM4EKMT2A | |
| Pivalate SCHEMBL28053669 | 0.64 | ALPL (0.30) | — | |
| SCHEMBL23595328 | 0.63 | — | — | |
| Pivalamide SCHEMBL6191682 | 0.62 | KMT2A (0.38) | KDM4EKMT2A | |
| SCHEMBL27889105 | 0.61 | KDM4E (0.40) | KDM4EKMT2A | |
| SCHEMBL27781774 | 0.61 | — | — | |
| Acetic Acid SCHEMBL1871815 | 0.60 | ALPL (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268635-B1 | HETEROCYCLIC COMPOUNDS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2015-06-10 | — | — | EP | disclosed |
| US-8372849-B2 | Heterocyclic compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-02-12 | — | — | US | disclosed |
| EP-2268635-A1 | HETEROCYCLIC COMPOUNDS | Taigen Biotechnology Co., Ltd. (TW) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009131598-A1 | HETEROCYCLIC COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264339-A1 | Heterocyclic Compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264339-A1 | Heterocyclic Compounds | AHR, NQO1, LTC4S | KDM4E 2742/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.